NCT01981551View on ClinicalTrials.gov

Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

December 30, 2018

Study Completion Date

December 1, 2023

Conditions
Desmoid TumorsAggressive Fibromatosis
Interventions
DRUG

PF-03084014

Treatment with the selective small-molecule \>=-secretase inhibitor PF- 3084014 caused significant tumor shrinkage in patients with unresectable desmoid tumors in an early-phase clinical trial.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01981551 - Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis | Biotech Hunter | Biotech Hunter